Rahul A. Parikh
Expertise in
14
conditions

Dr. Rahul A. Parikh

Oncology
4350 Shawnee Mission Parkway, 
Fairway, KS 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
25 Years of Experience
Expertise in
14
conditions
4350 Shawnee Mission Parkway, 
Fairway, KS 

Overview

Rahul Parikh is an Oncologist in Fairway, Kansas. Dr. Parikh has been practicing medicine for over 25 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, and Bladder Cancer. Dr. Parikh is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Seth Gordhandas Sunderdas Medical College And King Edward Memorial Hospital, Bachelor Of Medicine And Bachelor Of Surgery, 2001

Residency

University of Pittsburgh Medical Center, Internal Medicine, 2009

Specialties

Oncology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine, Medical Oncology - 2012

Fellowships

University of Pittsburgh, Hematology and Oncology, 2012

Hospital Affiliations

University Of Kansas Health System - St Francis Campus
University Of Kansas Hospital
Miami County Medical Center

Languages Spoken

English
Gujarati 
Hindi
Marathi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Clinical Research Center
4350 Shawnee Mission Parkway, Fairway, KS 66205
Other Locations
Richard and Annette Bloch Cancer Care Pavilion
2650 Shawnee Mission Parkway, Westwood, KS 66205
The University of Kansas Hospital
4000 Cambridge Street, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Avelumab, Peposertib, Radium-223
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Eribulin Mesylate
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Anti-OX40 Antibody PF-04518600, Axitinib
Study Phase: Phase 2
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Pazopanib Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Procedure, Other, Biological
Study Drugs: Pembrolizumab, Recombinant EphB4-HAS Fusion Protein
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Tremelimumab
Study Phase: Phase 2
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Anakinra, Dual PSMA-Specific/TGFbeta-Resistant CAR-T Cells
Study Phase: Phase 1
Registry for Proton Beam Radiation Therapy
Registry for Proton Beam Radiation Therapy
Enrollment Status: Completed
Publish Date: July 24, 2023
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Drug
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Enrollment Status: Completed
Publish Date: December 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial
STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial
Enrollment Status: Terminated
Publish Date: June 05, 2017
Intervention Type: Radiation
Study Phase: Not Applicable
View 16 Less Clinical Trials

34 Total Publications

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 20, 2026
Similar Doctors
Jeffrey M. Holzbeierlein
Expertise in
42
conditions
Dr. Jeffrey M. Holzbeierlein
Oncology
Expertise in
42
conditions
Dr. Jeffrey M. Holzbeierlein
Oncology

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (1.5 miles away)
913-588-1227
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Holzbeierlein is an Oncologist in Kansas City, Kansas. Dr. Holzbeierlein has been practicing medicine for over 32 years is highly rated in 42 conditions, according to our data. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Holzbeierlein is currently accepting new patients.

Tara L. Lin
Expertise in
15
conditions
Dr. Tara L. Lin
Oncology
Expertise in
15
conditions
Dr. Tara L. Lin
Oncology

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (1.2 miles away)
913-588-1227
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Lin is an Oncologist in Fairway, Kansas. Dr. Lin has been practicing medicine for over 26 years is highly rated in 15 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lin is currently accepting new patients.

Eugene K. Lee
Expertise in
31
conditions
Dr. Eugene K. Lee
Oncology
Expertise in
31
conditions
Dr. Eugene K. Lee
Oncology

The University Of Kansas Hospital

4000 Cambridge Street, 
Kansas City, KS 
 (1.6 miles away)
913-588-1227
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eugene Lee is an Oncologist in Kansas City, Kansas. Dr. Lee has been practicing medicine for over 21 years is highly rated in 31 conditions, according to our data. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Lee is currently accepting new patients.

Frequently Asked Questions about Dr. Rahul A. Parikh

How do I make an appointment with Dr. Rahul A. Parikh?

You can book an appointment with Dr. Rahul A. Parikh by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rahul A. Parikh a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rahul A. Parikh is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rahul A. Parikh specialize in?

While Dr. Rahul A. Parikh is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Urothelial Cancer, and Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Rahul A. Parikh participate in research or clinical trials?

Yes. Dr. Rahul A. Parikh has published 34 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Rahul A. Parikh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rahul A. Parikh accept my insurance?

Dr. Rahul A. Parikh accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parikh's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile